Review Article
Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
| TKIs | Compound name | Previous name | Company | Trade name | Approval by US, FDA | Dosage |
| First-generation TKI | Imatinib | STI571, CPG57148B | Novartis | Gleevac or Glivec | 2001 | CML-CP-400 mg once daily |
|
Second-generation TKIs | Nilotinib | AMN107 | Novartis | Tasigna | 2006 | CML- CP/AP-400 mg twice daily | Dasatinib | BMS354825 | Bristol-Myers Squibb | Sprycel | 2007 | CML-CP-100 mg once daily | Bosutinib | SKI606 | Pfizer | Bosulif | 2012 | 500 mg once daily |
| Third-generation TKI | Ponatinib | AP24534 | Ariad | Iclusig | 2013 | 45 mg once daily |
|
|
CP: chronic phase; AP: accelerated phase.
|